Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Celcuity Inc. (CELC)

NASDAQ: CELC · Services-Medical Laboratories · Minneapolis, MN

Our rating: Cautious

Cautious reaffirmed at $66.79, moderate conviction, November 6, 2026.

Breaks if: The cautious view would be proved wrong if Celcuity's stock trades durably above $90 within the next 12 months on the back of a positive pivotal clinical readout or a licensing deal carrying an upfront payment of $200M or more from an established pharmaceutical partner — either event would demonstrate that the pipeline value embedded in the filings exceeds what a cautious read of the available figures supports.

Key figures

Market value$2.6B
Revenue, last 12 monthsn/a
Net income, last 12 months−$256M
Free cash flow, last 12 months−$213M
Price to earningsn/a
Free cash flow yield−8.1%
Dividend yield0.0%
Operating marginn/a
Return on equity−1192.9%
Beta to the S&P 5001.12
Volatility, annualized124.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-1.33−$66M
June 30, 2026n/an/a$-1.44−$55M
March 31, 2026n/an/a$-0.97−$55M
December 31, 2025n/an/a$-0.98−$36M
September 30, 2025n/an/a$-0.92−$45M
June 30, 2025n/an/a$-1.04−$36M
March 31, 2025n/an/a$-0.86−$36M
December 31, 2024n/an/a$-0.87−$28M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

23 ledger entries and 41 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.